Abstract:Abstract Background As the most abundant internal mRNA modification, N 6 -methyladenosine (m 6 A) is associated with various cancers. However, RNA modification m 6 A has not been studied in chromophobe renal cell carcinoma (chRCC). The present study aimed to comprehensively analyze the global m 6 A modification pattern in chRCC. Methods Three subjects with chRCC were enrolled in our study. Transcriptome-wide m 6 A methylone and transcriptome analysis in chRCC and tumor-adjacent normal tissues were detected via m 6 A-SEAL-seq and RNA-sEq. m 6 A-modified mRNAs were further validated by m 6 A-immunoprecipition followed by quantitative real-time PCR (m 6 A-IP-qPCR). The least absolute shrinkage and selection operator (LASSO) Cox regression and multivariate Cox proportional hazards regression analysis were used to determine the candidate gene. Results We performed qPCR in six subjects of chRCC and found that the expression levels of m 6 A writer subunit WTAP, m 6 A erasers FTO and ALKBH5, and m 6 A reader YTHDF2 were significantly downregulated in chRCC tissues compared with corresponding tumor-adjacent normal tissues. In all three subjects, 12,841 confident m 6 A peaks representing 10,102 transcripts and 15,024 confident m 6 A peaks representing 11,396 transcripts were respectively identified in chRCC and tumor-adjacent normal tissues. Analysis of differential m 6 A levels identified 644 hypermethylated m 6 A peaks and 1,304 hypomethylated m 6 A peaks in chRCC compared with tumor-adjacent normal tissues. Gene Ontology (GO) analysis revealed that genes with hypomethylated m 6 A peaks (1,137) were associated with pathways in cancer. Compared with tumor-adjacent normal tissues, 3,911 genes were significantly dysregulated in chRCC, including 2,344 downregulated and 1,567 upregulated mRNAs. Functional enrichment analysis revealed that the dysregulated genes in chRCC were significantly enriched in multiple metabolic processes. We identified two hypomethylated genes NOTCH1 and FGFR1, which might respectively act as a tumor suppressor and an oncogene in chRCC. Three m 6 A-dependent signatures were identified using Cox regression screen and LASSO regression. Based on the significant prognostic signatures, we build a m 6 A-dependent prognostic model, with the Concordance index (C-index) = 0.96. The Kaplan-Meier survival curve and log-rank between the high-risk and low-risk group showed significant difference. Conclusions This study presented the first m 6 A transcriptome-wide profile of human chRCC, which may provide clues for the m 6 A methylation-based research on chRCC epitranscriptomic etiology and pathogenesis.

m<SUP>6</SUP>A-mRNA Methylation Regulates Gene Expression and Programmable m<SUP>6</SUP>A Modification of Cellular RNAs With CRISPR-Cas13b in Renal Cell Carcinoma

m6A-mRNA Methylation Regulates Gene Expression and Programmable m6A Modification of Cellular RNAs With CRISPR-Cas13b in Renal Cell Carcinoma

Rna N-6-Methyladenosine Methylation In Post-Transcriptional Gene Expression Regulation

Abstract 4827: N6-Methyladenosine Modification of LINC00901 Promotes Pancreatic Cancer Progression

Transcriptome-wide Landscape of RNA Modification N6-Methyladenosine in Chromophobe Renal Cell Carcinoma

N6-Methyladenosine Regulator-Mediated Methylation Modification Patterns with Distinct Prognosis, Oxidative Stress, and Tumor Microenvironment in Renal Cell Carcinoma

Establishment of a Risk Signature Based on M6a RNA Methylation Regulators That Predicts Poor Prognosis in Renal Cell Carcinoma

Comprehensive analysis of m6A methylome and transcriptome by Nanopore sequencing in clear cell renal carcinoma

N<SUP>6</SUP>-methyladenosine as a biological and clinical determinant in colorectal cancer: progression and future direction

Comprehensive Analyses of Molecular Features, Prognostic Values, and Regulatory Functionalities of M6a-Modified Long Non-Coding RNAs in Lung Adenocarcinoma.

N6-methyladenosine RNA Methylation Regulators Participate in Malignant Progression and Have Prognostic Value in Clear Cell Renal Cell Carcinoma

Transcriptome-Wide Map of N6-Methyladenosine Methylome Profiling in Human Bladder Cancer

m6A Methylation Patterns and Tumor Microenvironment Infiltration Characterization in Clear-Cell Renal Cell Carcinoma

RNA m<SUP>6</SUP>A methylation in cancer

N 6 ‐methyladenosine Steers RNA Metabolism and Regulation in Cancer

<scp>RNA m<sup>6</sup>A</scp> methylation in cancer

Understanding m6A changes in chromophobe renal cell carcinoma and predicting patient outcomes survival

RNA M6a Modification in Cancers: Molecular Mechanisms and Potential Clinical Applications.

N6-methyladenosine-mediated Gene Regulation and Therapeutic Implications.

The role of N6-methyladenosine (m6A) in kidney diseases

RNA m 6 A methylation in cancer.